The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Med.
Sec. Geriatric Medicine
Volume 11 - 2024 |
doi: 10.3389/fmed.2024.1464978
This article is part of the Research Topic Clinical Management of Older Persons with Cancer: Current Status and Future Directions View all 6 articles
Low Skeletal Muscle Mass as a Proxy Marker of Sarcopenia is a Risk Factor for Major Complications in Older Patients Undergoing Curative Colon Resections for Colon Cancer
Provisionally accepted- 1 Department of General Surgery, Başkent University, Ankara, Türkiye
- 2 Department of Radiology, Başkent University, Ankara, Türkiye
- 3 Department of Statistics, Başkent University, Ankara, Türkiye
- 4 Department of Internal Medicine, Division of Medical Oncology, Başkent University, Ankara, Türkiye
- 5 Department of Anesthesiology, Başkent University, Ankara, Türkiye
- 6 Department of General Surgery, Başkent University, Ankara, Türkiye
Introduction: Various reports have confirmed that low skeletal muscle mass, a proxy marker of sarcopenia, can be a risk factor for surgical and oncological outcomes in colon cancer. We aimed to investigate the effects of skeletal muscle mass index (SMMI) on postoperative complications, overall survival (OS), and disease-free survival (DFS) in older patients with colon cancer who underwent elective curative colon resections. Material and Methods: Patients over 65 years old with stage I-III colon cancer who underwent elective curative colon resections between January 2015 and December 2023 were included in this single-center retrospective longitudinal study. Demographics, comorbidities, laboratory data, pathological features, malignant lymph node ratio (MLNR), OS, and DFS were recorded. Controlling Nutritional Status (CONUT) Score was used to assess the nutritional status. An axial portal-phase image was obtained at the level of the third lumbar vertebra, and muscle areas were calculated. SMMI was calculated by dividing the muscle area (cm2) by the square of the patient’s height (m2). Low SMMI was defined as SMMI<41 cm2/m2 in women and <43 cm2/m2 in men with body mass index (BMI) <25 kg/m2, and as SMMI <53 cm2/m2 in patients with a BMI >25 kg/m2. Postoperative complications were classified according to the Clavien-Dindo system. Univariate and multivariate analyses were performed to investigate the factors related to the postoperative complications, OS and DFS. Results: In total, 98 cases (mean age 75.2 ±6.9, 55.1% male) were included in the study. The median follow-up time was 38.3 (0.5-113) months. There were 64 patients (65.3%) in the Low SMMI group and 34 patients (34.7%) in the Normal SMMI group. Logistic regression analysis demonstrated that low SMMI was associated with a higher risk of major complications, with an odds ratio of 5.3 (95% CI, 1.1-20.1; P=0.037). Cox regression analysis revealed no significant differences in OS and DFS. Conclusion: Low SMMI as a proxy marker of sarcopenia was found to be an independent risk factor for postoperative major complications. Additional prospective studies are warranted to obtain more reliable results.
Keywords: Colon Cancer, Sarcopenia, Skeletal Muscle Mass Index, Geriatrics, complication, Survival
Received: 15 Jul 2024; Accepted: 26 Dec 2024.
Copyright: © 2024 TIRNOVA, GASIMOVA, AKAY, Sarıtürk, Guvenmert, YENİDÜNYA and KARAKAYALI. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
İSMAİL TIRNOVA, Department of General Surgery, Başkent University, Ankara, Türkiye
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.